Donanemab:’The results may be misleading’ Hole Ousia 3 years ago Share this: Share on Facebook (Opens in new window) Facebook Share on X (Opens in new window) X Estimating the true value: Aducanumab and Donanemab for Early Alzheimer DiseaseDateJuly 20, 2023In relation toAlzheimer's diseaseBrain volume loss due to DonanemabDateJuly 20, 2023In relation toAlzheimer's diseaseAnti-amyloid drugs: Key questionsDateDecember 6, 2023In relation toAlzheimer's disease
